New from the nonspecialty journals: Booster shots OK in juvenile arthritis; suggestions for screening after fungus-contaminated methylprednisolone injections; another manifestation of IgG4-related disease, and more.
The FDA has approved canakinumab (Ilaris) for treatment of active systemic juvenile idiopathic arthritis) in patients aged 2 years and older. The drug is administered monthly by subcutaneous injection.
Two major examples of "crowdsourcing" genetic explanations for rheumatic diseases: a competition to explain the genetics of anti-TNF response in rheumatoid arthritis, and 14 newfound genes for juvenile idiopathic arthritis.
An analysis of adverse events in 17 global clinical trials of adalimumab (Humira) confirms the drug’s safety profile over nearly a dozen years of use for rheumatoid arthritis and other inflammatory disorders. Serious infections were the most common side effect.